Trial Profile
An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs ATYR 1940 (Primary)
- Indications Facioscapulohumeral muscular dystrophy
- Focus Adverse reactions; Pharmacodynamics
- Sponsors aTyr Pharma
- 13 Aug 2021 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
- 14 Nov 2017 According to an aTyr Pharma media release, in october data was presented at the 22nd International Annual Congress of the World Muscle Society.
- 27 Sep 2017 Results presented in an aTyr Pharma Media Release.